About: Clinical and biological role of secretory phospholipase A2 in acute respiratory distress syndrome infants

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical and biological role of secretory phospholipase A2 in acute respiratory distress syndrome infants Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Clinical and biological role of secretory phospholipase A2 in acute respiratory distress syndrome infants
Creator	Antonelli, Massimo De Luca, Daniele Piastra, Marco Capoluongo, Ettore Conti, Giorgio Echaide, Mercedes Gentile, Leonarda Lopez-Rodriguez, Elena Minucci, Angelo Perez-Gil, Jesus Stival, Eleonora Vendittelli, Francesca
Source	PMC
abstract	INTRODUCTION: Secretory phospholipase A2 is supposed to play a role in acute lung injury but no data are available for pediatric acute respiratory distress syndrome (ARDS). It is not clear which enzyme subtypes are secreted and what the relationships are between enzyme activity, biophysical and biochemical parameters, and clinical outcomes. We aimed to measure the enzyme and identify its subtypes and to study its biochemical and biophysical effect. The secondary aim was to correlate enzyme activity with clinical outcome. METHODS: Bronchoalveolar lavage was performed in 24 infants with ARDS and 14 controls with no lung disease. Samples were assayed for secretory phospholipase A2 and molecules related to its activity and expression. Western blotting and captive bubble surfactometry were also performed. Clinical data were real time downloaded. RESULTS: Tumor necrosis factor-α (814 (506-2,499) vs. 287 (111-1,315) pg/mL; P = 0.04), enzyme activity (430 (253-600) vs. 149 (61-387) IU/mL; P = 0.01), free fatty acids (4.3 (2.8-8.6) vs. 2 (0.8-4.6) mM; P = 0.026), and minimum surface tension (25.6 ± 6.1 vs. 18 ± 1.8 mN/m; P = 0.006) were higher in ARDS than in controls. Phospholipids are lower in ARDS than in controls (76.5 (54-100) vs. 1,094 (536-2,907) μg/mL; P = 0.0001). Three enzyme subtypes were identified (-IIA, -V, -X), although in lower quantities in controls; another subtype (-IB) was mainly detected in ARDS. Significant correlations exist between enzyme activity, free fatty acids (ρ = 0.823; P < 0.001), and surface tension (ρ = 0.55; P < 0.028). Correlations also exist with intensive care stay (ρ = 0.54; P = 0.001), PRISM-III(24 )(ρ = 0.79; P< 0.001), duration of ventilation (ρ = 0.53; P = 0.002), and oxygen therapy (ρ = 0.54; P = 0.001). CONCLUSIONS: Secretory phospholipase A2 activity is raised in pediatric ARDS and constituted of four subtypes. Enzyme correlates with some inflammatory mediators, surface tension, and major clinical outcomes. Secretory phospholipase A2 may be a clinically relevant target in pediatric ARDS.
has issue date	2013-07-24(xsd:dateTime)
bibo:doi	10.1186/cc12842
bibo:pmid	23883784
has license	cc-by
sha1sum (hex)	dd30d7971d2ab4ee8d5631bbfc2e3b75cc828209
schema:url	https://doi.org/10.1186/cc12842
resource representing a document's title	Clinical and biological role of secretory phospholipase A2 in acute respiratory distress syndrome infants
has PubMed Central identifier	PMC4057254
has PubMed identifier	23883784
schema:publication	Crit Care
resource representing a document's body	covid:dd30d7971d2ab4ee8d5631bbfc2e3b75cc828209#body_text
is schema:about of	named entity 'phospholipase' named entity 'surface tension' named entity 'ARDS' named entity 'phospholipase' named entity '028' named entity 'EFFECT' named entity 'PHOSPHOLIPASE A2 ACTIVITY' named entity '0.01' named entity 'EXPRESSION' named entity 'BIOPHYSICAL' named entity 'controls' named entity 'activity' named entity 'assayed' named entity 'Correlations' named entity 'enzyme' named entity 'constituted' named entity 'aim' named entity 'subtypes' named entity 'biophysical' named entity 'acute lung injury' named entity 'Phospholipids' named entity 'acute respiratory distress syndrome' named entity 'ARDS' named entity 'Enzyme' named entity 'surface tension' named entity 'ARDS' named entity 'Tumor necrosis factor-α' named entity 'ARDS' named entity 'pediatric' named entity 'Phospholipids' named entity 'enzyme activity' named entity 'HFOV' named entity 'ARDS' named entity 'respiratory support' named entity 'mechanical ventilation' named entity 'pediatric' named entity 'sPLA2' named entity 'BALF' named entity 'CBS' named entity 'catheter' named entity 'HFOV' named entity 'FFA' named entity 'proof of concept' named entity 'isotypes' named entity 'plateau pressure' named entity 'arterial oxygen saturation' named entity 'PICU' named entity 'epithelial lining fluid' named entity 'TNFα' named entity 'sPLA2' named entity 'mammalians' named entity 'ARDS' named entity 'TNFα' named entity 'surface tension' named entity 'ARDS' named entity 'Billerica' named entity 'intensive care units' named entity 'acute respiratory distress syndrome' named entity 'PICU' named entity 'substrate specificity' named entity 'clinical data' named entity 'sPLA2' named entity 'sPLA2' named entity 'FFA' named entity 'surface tension' named entity 'bromophenol blue' named entity 'informed consent' named entity 'partial correlation' named entity 'non-fat dry milk' named entity 'sPLA2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software